Market Failure and the Poverty of New Drugs in Maternal Health

Nicholas M Fisk () and Rifat Atun

Working Papers from eSocialSciences

Abstract: A new survey finds that only 17 drugs are under active development for maternal health indications, which is less than 3% of the pipeline in cardiovascular health (660 drugs). The international agencies have forgotten pregnant women. Given the unacceptably high number of maternal and perinatal deaths each year, it is high time to address this issue. [Policy Forum January 2008, Volume 5, Issue 1].

Keywords: maternal health; drugs; development; pregnant women; perinatal deaths; Millennium Development Goals; MDGs; obstetrics; fetal; foetal; growth; research and development; R&D; patent protection; US; United States; Europe; pregnancy; obstructed labour; mortality; pharmaceutical companies; neurology (search for similar items in EconPapers)
Date: 2008-01
Note: Institutional Papers
References: View complete reference list from CitEc
Citations: View citations in EconPapers (2)

Downloads: (external link)
http://www.esocialsciences.org/Download/repecDownl ... &AId=1360&fref=repec

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:ess:wpaper:id:1360

Access Statistics for this paper

More papers in Working Papers from eSocialSciences
Bibliographic data for series maintained by Padma Prakash ().